Trials / Completed
CompletedNCT04300647
A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 172 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of tiragolumab in combination with atezolizumab and atezolizumab monotherapy in patients with programmed death-ligand 1 (PD-L1)-positive cervical cancer (metastatic and/or recurrent).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tiragolumab | Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
| DRUG | Atezolizumab | Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle. |
Timeline
- Start date
- 2020-06-30
- Primary completion
- 2021-12-08
- Completion
- 2025-02-24
- First posted
- 2020-03-09
- Last updated
- 2026-03-12
- Results posted
- 2025-02-07
Locations
58 sites across 17 countries: United States, Australia, Brazil, Canada, Costa Rica, France, Italy, Mexico, Panama, Peru, Poland, Russia, South Korea, Spain, Taiwan, Thailand, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04300647. Inclusion in this directory is not an endorsement.